Pulse Biosciences (PLSE)
NASDAQ:PLSE
Want to see PLSE full AI Analyst Report?
PLSE Stock Chart & Stats
$23.40
-$0.27(-1.46%)
At close: 4:00 PM EST
$23.40
-$0.27(-1.46%)
Day’s Range― - ―
52-Week Range$12.56 - $28.53
Previous CloseN/A
Volume31.18K
Average Volume (3M)189.63K
Market Cap
$1.77B
Enterprise Value$1.70B
Total Cash (Recent Filing)$68.32M
Total Debt (Recent Filing)$7.16M
Price to Earnings (P/E)―
Beta1.52
Next Earnings
Aug 12, 2026EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.09
Shares Outstanding69,209,710
10 Day Avg. Volume222,519
30 Day Avg. Volume189,626
Financial Highlights & Ratios
PEG Ratio-0.73
Price to Book (P/B)11.47
Price to Sales (P/S)2643.82
P/FCF Ratio-17.00
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue2.26K
Enterprise Value/Gross Profit-2.49K
Enterprise Value/Ebitda-22.95
Forecast
1Y Price Target
$31.00Price Target Upside32.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.1
Revenue Forecast (FY)$2.63M
Bulls Say, Bears Say
Bulls Say
Strong Clinical Efficacy & Safety (European Feasibility)Robust, reproducible feasibility outcomes (high procedural success, durable 12‑month results and very low SAE rate) create a durable clinical differentiation versus thermal ablation. This data supports regulatory filings, physician adoption and premium positioning in the growing AF ablation market over the next 2–6 months and beyond.
U.S. Pivotal IDE Trial Initiated And Enrollment AcceleratedInitiation and acceleration of the pivotal IDE trial materially de-risks the regulatory timeline. A shortened enrollment and Bayesian design shorten follow‑up and can materially reduce time to PMA submission, improving the company’s path to commercialization and creating a lasting step toward market access.
Capital Equipment + Recurring Consumables Revenue ModelAn installed‑base model (console sales plus single‑use disposables) offers a durable, scalable revenue stream as procedure volume grows. Consumables tied to each treatment align revenue with clinical adoption and can convert early procedural wins into recurring cash flow as clinicians scale use.
Bears Say
Large Ongoing Cash BurnSustained negative operating and free cash flow indicate material ongoing financing need. Unless clinical milestones translate quickly into higher revenue or cash requirements fall, the company will depend on external funding, creating execution and dilution risk over the coming months.
Deep Unprofitability And Negative Gross ProfitNegative gross profit and very large net losses show the cost base is far ahead of current sales. Structural margin improvement is required to reach sustainable profitability; until meaningful scale or cost restructuring occurs, losses will continue to erode equity and constrain strategic flexibility.
Commercial Immaturity And Financing RelianceVery limited product revenue versus high quarterly cash burn leaves the company reliant on warrant exercises, ATM/shelf programs and potential dilution. Commercial scale is nascent, so near‑term execution and financing outcomes will materially affect runway and long‑term independence.
Pulse Biosciences News
PLSE FAQ
What was Pulse Biosciences’s price range in the past 12 months?
Pulse Biosciences lowest stock price was $12.56 and its highest was $28.53 in the past 12 months.
What is Pulse Biosciences’s market cap?
Pulse Biosciences’s market cap is $1.77B.
When is Pulse Biosciences’s upcoming earnings report date?
Pulse Biosciences’s upcoming earnings report date is Aug 12, 2026 which is in 52 days.
How were Pulse Biosciences’s earnings last quarter?
Pulse Biosciences released its earnings results on May 04, 2026. The company reported -$0.238 earnings per share for the quarter, beating the consensus estimate of -$0.27 by $0.032.
Is Pulse Biosciences overvalued?
According to Wall Street analysts Pulse Biosciences’s price is currently Undervalued.
Does Pulse Biosciences pay dividends?
Pulse Biosciences does not currently pay dividends.
What is Pulse Biosciences’s EPS estimate?
Pulse Biosciences’s EPS estimate is -0.29.
How many shares outstanding does Pulse Biosciences have?
Pulse Biosciences has 69,209,710 shares outstanding.
What happened to Pulse Biosciences’s price movement after its last earnings report?
Pulse Biosciences reported an EPS of -$0.238 in its last earnings report, beating expectations of -$0.27. Following the earnings report the stock price went down -3.841%.
Which hedge fund is a major shareholder of Pulse Biosciences?
Currently, no hedge funds are holding shares in PLSE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pulse Biosciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$31.00 (32.48% Upside)
$31.00 (32.48% Upside)
Blogger Sentiment
Bullish
PLSE Sentiment 75%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 31.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $13.3M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-15.46%
12-Months-Change
Fundamentals
Return on Equity
-86.67%
Trailing 12-Months
Asset Growth
-38.81%
Trailing 12-Months
Company Description
Pulse Biosciences
Pulse Biosciences, Inc. is an innovative firm specializing in bioelectric medicine. Their primary offering is the CellFX System, a sophisticated, console-based platform that is precisely controlled via software. This system utilizes its proprietary Nano-Pulse Stimulation technology to deliver extremely brief, nanosecond-duration electrical pulses. This advanced method is designed to selectively eliminate target cells without thermal damage, effectively safeguarding adjacent non-cellular tissue. The CellFX System is applied in the treatment of various medical conditions. The company, originally incorporated in 2014 as Electroblate, Inc., officially became Pulse Biosciences, Inc. in December 2015. Its corporate headquarters are situated in Hayward, California.
PLSE Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized substantial clinical progress and clear operational momentum: landmark European feasibility results (strong efficacy and low SAE rate), initiation and acceleration of the U.S. pivotal IDE trial, regulatory milestones and expanded clinical programs (surgical clamp and Vybrance). These positive milestones were balanced against near‑term commercial immaturity (very small product revenue), rising R&D/clinical spend driving wider GAAP and non‑GAAP losses, and a material quarterly cash burn that reduced cash balances. Management has strengthened leadership, prioritized the high‑value catheter program and secured financing flexibility (shelf and ATM) to support execution. On balance, the clinical and operational advances meaningfully outweigh the financial and timing challenges reported.View all PLSE earnings summariesPLSE Stock 12 Month Forecast
Average Price Target
$31.00
▲(32.48% Upside)
Technical Analysis
Ownership Overview
73.02% Insiders
2.26% Mutual Funds
1.81% Other Institutional Investors
20.27% Public Companies and
Individual Investors